Key references

  1. Bullet‘‘Does this patient have...’’ ‘‘Is this patient at risk for infection with multidrug resistant bacteria.pdf

  2. Bullet‘Plus c ̧a change’ for the future of sepsis.pdf

  3. Bullet1,3-β-D-Glucan in Patients Receiving Intravenous Amoxicillin–Clavulanic Acid.pdf

  4. Bullet4G5G Polymorphism of Plasminogen Activator is associated with ICU mortality .pdf

  5. BulletA Candida auris Outbreak and Its Control in an Intensive Care Setting.pdf

  6. BulletA Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically Ill Patients.pdf

  7. BulletA Conceptual and Adaptable Approach to Hospital Preparedness for Acute Surge Events Due to Emerging Infectious Diseases.pdf

  8. BulletA Critical Analysis of the Literature on Time-to- Antibiotics in Suspected Sepsis Review 2020.pdf

  9. BulletA First Unexplained Invasive Encapsulated Bacterial Infection in Young Adults Associated With High Mortality and Readmission Rates.pdf

  10. BulletA global accounting of sepsis 2020.pdf

  11. BulletA higher dose of vancomycin in continuous infusion is needed in critically ill patients.pdf

  12. BulletA Molecular Biomarker to Diagnose Community-acquired Pneumonia on Intensive Care Unit Admission.pdf

  13. BulletA Multicenter Evaluation of Prolonged Empiric Antibiotic Therapy.pdf

  14. BulletA Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.pdf

  15. BulletA New Multiplex Molecular Tool to Assess the Immune Status of Critically Ill Patients.pdf

  16. BulletA New Series of Sorbent Devices for Multiple Clinical Purposes.pdf

  17. BulletA randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia.pdf

  18. BulletA role for plasma exchange in counterbalancing the host response in sepsis 2019.pdf

  19. BulletA survey on antimicrobial dosing and monitoring in ICUs.pdf

  20. BulletA survey on infection management practices in Italian ICUs.pdf

  21. BulletAbdominal sepsis.pdf

  22. BulletAccuracy of the clinical pulmonary infection score to differentiate ventilator-associated tracheobronchitis from ventilator-associated pneumonia 2020.pdf

  23. BulletAccuracy of ventilator associated events for the diagnosis of ventilator associated lower respiratory tract infections 2020.pdf

  24. BulletAcetaminophen for Fever in Critically Ill Patients with Suspected Infection.pdf

  25. BulletAcinetobacter baumannii infections in the ICU 2015.pdf

  26. BulletAcinetobacter infection Review 2019.pdf

  27. BulletAcinetobacter Infection Review.pdf

  28. BulletActivation and Regulation of Systemic Inflammation in ARDS.pdf

  29. BulletActivity of ceftazidime:avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa.pdf

  30. BulletAcute bacterial meningitis in adults Review 2016.pdf

  31. BulletAcute bacterial meningitis in adults.pdf

  32. BulletAcute encephalitis Review 2019.pdf

  33. BulletAcute Infection and Myocardial Infarction Review 2019.pdf

  34. BulletAcute Infection in the Immunocompromised Host.pdf

  35. BulletAcute Interstitial Pneumonia.pdf

  36. BulletAcute kidney injury taking aim at colistin.pdf

  37. BulletAcute respiratory failure in immunocompromised adults Review 2018.pdf

  38. BulletAcute Viral Encephalitis Review 2018.pdf

  39. BulletAdditional Trials of Vitamin C in Septic Shock 2020.pdf

  40. BulletAdequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality.pdf

  41. BulletAdjunctive Corticosteroid Treatment in Septic Shock Review 2019.pdf

  42. BulletAdjunctive Glucocorticoid Therapy in Patients with Septic Shock  ADRENAL Trial 2018.pdf

  43. BulletAdjustment of dosing of antimicrobial agents for bodyweight in adults.pdf

  44. BulletAdrenomedullin.pdf

  45. BulletAdult Bacterial Meningitis Earlier Treatment and Improved Outcome Following Guideline Revision Promoting Prompt Lumbar Puncture.pdf

  46. BulletAdult early management of meningitis and meningococcal septicemia.pdf

  47. BulletAdvances in antibiotic therapy in the critically ill.pdf

  48. BulletAdvances in source control.pdf

  49. BulletAdvances in the Diagnosis and Management of Invasive Fungal Disease Review 2019.pdf

  50. BulletAdvances in the prevention, management, and treatment of community-acquired pneumonia.pdf

  51. BulletAdverse Events With Antibiotic Use.pdf

  52. BulletAdverse outcomes associated with contact precautions review.pdf

  53. BulletAeosolized colistin for VAP.pdf

  54. BulletAerosolized Antibiotics for Treating Pneumonia.pdf

  55. BulletAerosolized Antibiotics for Ventilator associated Pneumonia review 2012.pdf

  56. BulletAerosolized antibiotics review 2013.pdf

  57. BulletAerosolized Antibiotics Review 2016.pdf

  58. BulletAggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive care unit acquired infection.pdf

  59. BulletAirway invasive aspergillosis with organizing pneumonia.pdf

  60. BulletAmikacin pharmacokinetic:pharmacodynamic in intensive care unit.pdf

  61. BulletAminoglycoside dosing review.pdf

  62. BulletAminoglycosides nephrotoxicity.pdf

  63. BulletAn alternate pathophysiologic paradigm of sepsis and septic shock Kumar Review 2014.pdf

  64. BulletAn approach to antibiotic treatment in patients with sepsis Review 2020.pdf

  65. BulletAn Evaluation of Environmental Decontamination With Hydrogen Peroxide Vapor for Reducing the Risk of Patient Acquisition of Multidrug-Resistant Organisms.pdf

  66. BulletAn overview on severe infections in Europe.pdf

  67. BulletAnti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?.pdf

  68. BulletAntibiotic dosing in critical illness.pdf

  69. BulletAntibiotic dosing in obesity.pdf

  70. BulletAntibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units.pdf

  71. BulletAntibiotic Lock Technique Review.pdf

  72. BulletAntibiotic Prescription for Community-Acquired Pneumonia in the Intensive Care Unit.pdf

  73. BulletAntibiotic resistance and dose review.pdf

  74. BulletAntibiotic resistance mechanisms in the intensive care unit review 2013.pdf

  75. BulletAntibiotic stewardship in the intensive care unit review 2014.pdf

  76. BulletAntibiotic strategies in the era of multidrug resistance.pdf

  77. BulletAntibiotics 5 Myths Debunked.pdf

  78. BulletAntibiotics for Sepsis Does Each Hour Really Count? Singer.pdf

  79. BulletAntibiotics for Sepsis—Finding the Equilibrium.pdf

  80. BulletAntibiotics from prehistory to the present day.pdf

  81. BulletAntibiotics in critically ill patients a systematic review of the pharmacokinetics.pdf

  82. BulletAntifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis.pdf

  83. BulletAntimicrobial central venous catheters in adults Review.pdf

  84. BulletAntimicrobial De-escalation in the Intensive Care Unit Review 2016.pdf

  85. BulletAntimicrobial de-escalation is part of appropriate antibiotic usage in ICU.pdf

  86. BulletAntimicrobial resistance in intensive care units.pdf

  87. BulletAntimicrobial-associated harm in critical care Review 2020.pdf

  88. BulletAntimicrobials optimizing their rational use in intra-abdominal infections Review 2016.pdf

  89. BulletApoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction.pdf

  90. BulletAppropriate antibiotic dosing in severe sepsis and acute renal failure edit.pdf

  91. BulletAppropriate antibiotic therapy in severe sepsis and septic shock does the dose matter.pdf

  92. BulletAppropriate Antibiotic Treatment in Severe Sepsis and Septic Shock Timing is everything.pdf

  93. BulletAre Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients.pdf

  94. BulletAre macrolides now obligatory in severe community-acquired pneumonia?.pdf

  95. BulletAre standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?.pdf

  96. BulletAre tracheal surveillance cultures useful in the intensive care unit? Review 2018.pdf

  97. BulletArterial Catheter blood stream infections in the ICU.pdf

  98. BulletArterial catheter-related bloodstream infections.pdf

  99. BulletArterial Catheters as a Source of Bloodstream Infection review 2014.pdf

  100. BulletAs Galactomannan Disappoints, Our Quest for a Feasible Diagnostic Standard for Invasive Aspergillosis Continues.pdf

  101. BulletAscorbic acid, corticosteroids, and thiamine in sepsis Review 2018.pdf

  102. BulletAspergillosis Clinical details.pdf

  103. BulletAspergillus Galactomannan for Diagnosing Invasive Aspergillosis.pdf

  104. BulletAspergillus-positive lower respiratory tract samples in patients with the acute respiratory distress syndrome.pdf

  105. BulletAspiration Pneumonia Review 2019.pdf

  106. BulletAssociation between Source of Infection and Hospital Mortality in Patients Who Have Septic Shock.pdf

  107. BulletAssociation between timing of antibiotic administration and mortality from septic shock.pdf

  108. BulletAssociation between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia.pdf

  109. BulletAssociation Between Vancomycin Minimum Inhibitory Concentration and Mortality Among PatientsWith Staphylococcus aureus Bloodstream Infections.pdf

  110. BulletAssociation of Azithromycin Use With Cardiovascular Mortality.pdf

  111. BulletAssociations Between Ventilator Bundle Components and Outcomes.pdf

  112. BulletAttributable mortality of ventilator-associated pneumonia.pdf

  113. BulletAugmented Renal Clearance in the ICU.pdf

  114. BulletAutopsy results of infection in H1N1.pdf

  115. BulletAzithromycin The Holy Grail to Prevent Exacerbations in Chronic Respiratory Disease?.pdf

  116. Bulletb D Glucan Assay for the Diagnosis of Invasive Fungal Infections Review.pdf

  117. Bulletb-D-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis.pdf

  118. BulletBacteremic Complications of Intravascular Catheters Colonized with Staphylococcus aureus.pdf

  119. BulletBacterial coinfection in influenza.pdf

  120. BulletBacterial contamination of surgical scrub suits worn outside the operating theatre.pdf

  121. BulletBacterial meningitis and neurological complications in adults.pdf

  122. BulletBacterial Meningitis Earlier Treatment and Improved Outcome Following Guideline Revision Promoting Prompt Lumbar Puncture.pdf

  123. BulletBacterial meningitis review 2012.pdf

  124. BulletBacterial meningitis review.pdf

  125. BulletBacterial Pneumonias in Immunocompromised Patients Review 2019.pdf

  126. BulletBacterial Quorum Sensing Its Role in Virulence and Possibilities for Its Control.pdf

  127. BulletBacterial translocation in shock edit.pdf

  128. BulletBactericidal antibiotics temporarily increase inflammation and worsen acute kidney injury.pdf

  129. BulletBacteriophage therapy.pdf

  130. BulletBacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections.pdf

  131. BulletBAL for VAP.pdf

  132. BulletBartlett's 2013 Review Advances in Infectious Diseases.pdf

  133. BulletBeta-Lactam Infusion in Severe Sepsis (BLISS).pdf

  134. BulletBeta-Lactam Monotherapy vs beta-Lactam–Macrolide Combination Treatment in Moderately Severe Community Acquired Pneumonia.pdf

  135. BulletBeware the siren’s song of novel endotracheal tube designs.pdf

  136. BulletBiofilm formation on three different endotracheal tubes.pdf

  137. BulletBiofilms and antibiotic resistance.pdf

  138. Bullet Blood Cultures in the Critical Care Unit Review.pdf

  139. BulletBlood Purification and Mortality in Sepsis and Septic Shock Review 2019.pdf

  140. BulletBlood purification in sepsis 2018.pdf

  141. BulletBNP for prediction of mortality in sepsis Review 2012.pdf

  142. BulletBNP in evaluation of intensive care unit shock.pdf

  143. BulletC Diff Review.pdf

  144. BulletBTS CAP Guideline Summary of Recommendations.pdf

  145. BulletC-Reactive Protein Kinetics after Major Surgery.pdf

  146. BulletCan a Lack of Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae Rectal Carriage Help Avoid Carbapenem Prescription.pdf

  147. BulletCan One Prescribe Carbapenems to Patients With IgE-Mediated Allergy to Penicillins or Cephalosporins Review 2014.pdf

  148. BulletCan Polymyxins Be Used for Multidrug-Resistant Organisms.pdf

  149. BulletCan procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia.pdf

  150. BulletCandida auris Review 2017.pdf

  151. BulletCandida colonization in ventilated ICU patients EDIT.pdf

  152. BulletCandida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment.pdf

  153. BulletCandida infection in ICU Review.pdf

  154. BulletCandida infection in ICU.pdf

  155. BulletCandida Infection Review.pdf

  156. BulletCandida pneumonia in ICU.pdf

  157. BulletCarbapenem antibiotics for serious infections Review 2012.pdf

  158. BulletCarbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin- Tazobactam for Patients With Extended- Spectrum β-Lactamase Bacteremia.pdf

  159. BulletCarbapenem-Resistant Enterobacteriaceae.pdf

  160. BulletCarbapenems Review.pdf

  161. BulletCarbapenems for Extended- Spectrum Lactamase Producing Bacteria.pdf

  162. BulletCardiotoxicity during Invasive Pneumococcal Disease.pdf

  163. BulletCaring for AIDS Patients in the ICU edit plus guidelines .pdf

  164. BulletCase report of Meningococcal sepsis.pdf

  165. BulletCaspofungin in intraabdominal sepsis.pdf

  166. BulletCatheter infection in ICU Evidence.pdf

  167. BulletCatheter related infections in ICU Review.pdf

  168. BulletCatheter-Associated Urinary Tract Infections.pdf

  169. BulletCatheter-related infections in patients with haematological malignancies.pdf

  170. BulletCauses of encephalitis and differences in their clinical presentations in England.pdf

  171. BulletCDC guidelines on Central Venous Catheter Infection.pdf

  172. BulletCeftazidime-avibactam versus meropenem for the treatment of nosocomial pneumonia.pdf

  173. BulletCentral line infections Review.pdf

  174. BulletCentral Line-Associated CDC Bloodstream Infection and Non-central line-associated Bloodstream Infection 2015.pdf

  175. BulletCentral venous catheter associated infections in the ICU Dutch approach.pdf

  176. BulletCentral venous catheter associated infections in the ICU Dutch approach.pdf

  177. BulletCentral-line bundles need a multimodal implementation strategy.pdf

  178. BulletCerebrospinal fluid lactate concentraton to distinguish bacterial from aseptic meningitis.pdf

  179. BulletChanges in lung microbiome do not explain the development of ventilator-associated pneumonia 2019.pdf

  180. BulletChanging pharyngeal flora of hospitalized patients.pdf

  181. BulletCharacteristics of critically ill influenza patients in an intensive care unit in the Netherlands.pdf

  182. BulletChlorhexidine Bathing and Health Care–Associated Infections.pdf

  183. BulletChlorhexidine bathing and health care-associated infections.pdf

  184. BulletClarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis.pdf

  185. BulletClassification of patients with sepsis according to blood genomic endotype.pdf

  186. BulletClearance of inflammatory cytokines in patients with septic acute kidney injury during renal replacement therapy using the EMiC2 filter.pdf

  187. BulletClinical and Pathophysiological Overview of Acinetobacter Infections Review 2017.pdf

  188. BulletClinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock.pdf

  189. BulletClinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults.pdf

  190. BulletClinical efficacy of once daily amikacin.pdf

  191. BulletClinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.pdf

  192. BulletClinical Management of Staphylococcus aureus Bacteremia review 2014.pdf

  193. BulletClinical Outcomes Associated With Procalcitonin Algorithms to Guide Antibiotic Therapy in Respiratory Tract Infections.pdf

  194. BulletClinical Practice Guideline for the Management of Candidiasis 2016.pdf

  195. BulletClinical Practice Guidelines for Clostridium difficile Infection in Adults and Children 2017.pdf

  196. BulletClinical pulmonary infection score (CPIS) for ventilator-associated pneumonia accuracy and inter-observer variability.pdf

  197. BulletClinically relevant pharmacokinetic knowledge on antibiotic dosing among intensive care professionals is insufficient.pdf

  198. BulletClostridioides difficile infection in the critically ill.pdf

  199. BulletClostridioides difficile Review 2019.pdf

  200. BulletClostridium Difficile Colitis review.pdf

  201. BulletClostridium difficile Colitis.doc

  202. BulletClostridium difficile in Adults Review 2015.pdf

  203. BulletClostridium difficile infection in the intensive care unit Review 2017.pdf

  204. BulletClostridium difficile infection.pdf

  205. BulletClostridium difficile review.pdf

  206. BulletClostridium Difficile.pdf

  207. BulletCo-infection in severe influenza.pdf

  208. BulletCognitive decline after sepsis Review 2015.pdf

  209. BulletColistin review.pdf

  210. BulletColistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.pdf

  211. BulletColistin-resistant Acinetobacter baumannii beyond carbapenem resistance..pdf

  212. BulletCombination Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia.pdf

  213. BulletCombined use of serum (1,3)-β-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia.pdf

  214. BulletCommunity acquired pneumonia admitted to ITU GenoSept.pdf

  215. BulletCommunity acquired Pneumonia in Adults Review.pdf

  216. BulletCommunity-acquired necrotizing pneumonia due to methicillin sensitive Staphylococcus aureus secreting Panton Valentine leukocidin review 2011.pdf

  217. BulletCommunity-acquired pneumonia in critically ill very old patients.pdf

  218. BulletCommunity-Acquired Pneumonia Pathogenesis of Acute Cardiac Events and Potential Adjunctive  Therapies Review 2016.pdf

  219. BulletCommunity-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers.pdf

  220. BulletCommunity-acquired pneumonia Review 2016.pdf

  221. BulletComparative Effectiveness of Beta-Lactams Versus Vancomycin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.pdf

  222. BulletComparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients.pdf

  223. BulletComparison between procalcitonin and C-reactive protein to predict blood culture results in ICU patients.pdf

  224. BulletComparison of alcoholic chlorhexidine and povidone–iodine cutaneous antiseptics for the prevention of central venous catheter-related infection.pdf

  225. BulletComparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy.pdf

  226. BulletComplications of Antibiotic Therapy Review.pdf

  227. BulletComplications of flu.pdf

  228. BulletContamination of Health Care Personnel During Removal of Personal Protective Equipment.pdf

  229. BulletContinuous administration of linezolid in pneumonia.pdf

  230. BulletContinuous and Prolonged Intravenous β-Lactam Dosing Implications for the Clinical Laboratory 2016.pdf

  231. BulletContinuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy.pdf

  232. BulletContinuous infusion of β-lactam antibiotics for all critically ill patients.pdf

  233. BulletContinuous meropenem infusion in ITU patients letter.pdf

  234. BulletContinuous versus Intermittent b-Lactam Infusion in Severe Sepsis.pdf

  235. BulletConvalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1.pdf

  236. BulletConvergence of carbapenem-resistance and hypervirulence in Klebsiella pneumoniae.pdf

  237. BulletCoronavirus epidemic preparing for extracorporeal organ support in intensive care.pdf

  238. BulletCorticosteroids for community-acquired pneumonia 2016.pdf

  239. BulletCorticosteroids for Community-Acquired Pneumonia Overstated Benefits and Understated Risks.pdf

  240. BulletCorticosteroids for Influenza Pneumonia.pdf

  241. BulletCorticosteroids for pneumonia Review 2018.pdf

  242. BulletCorticosteroids for Severe Community-Acquired Pneumonia.pdf

  243. BulletCotrimoxazole - optimal dosing in the critically ill.pdf

  244. BulletCOVID-19 Infection Review.pdf

  245. BulletCOVID-19 What we’ve done well and what we could or should have done better.pdf

  246. BulletCranial Imaging and Lumbar Puncture in Patients With Suspected Central Nervous System Infection.pdf

  247. BulletCreating resistant

  248. BulletCritical care management of adults with community-acquired severe respiratory viral infection Review 2020.pdf

  249. BulletCritical care management of infectious meningitis and encephalitis Review 2020.pdf

  250. BulletCritical illness and flat batteries Mervyn Singer.pdf

  251. BulletCritical Illness in Patients With Asplenia Review 2016.pdf

  252. BulletCritical Staph Pneumonia Complicating Early-Stage Pregnancy.pdf

  253. BulletCT before lumbar puncture in meningitis.pdf

  254. BulletCulture-Negative Severe Sepsis.pdf

  255. BulletCumulative Evidence of Randomized Controlled and Observational Studies on Catheter-Related Infection Risk of Central Venous Catheter Insertion Site in ICU Patients.pdf

  256. BulletCurrent and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.pdf

  257. BulletCurrent approaches to the diagnosis of bacterial and fungal bloodstream infections in the intensive care unit Review 2012.pdf

  258. BulletCurrent concepts in anti-tuberculosis treatment in the critically ill patient.pdf

  259. BulletCurrent Controversies in Sepsis Management 2020.pdf

  260. BulletCurrent controversies in the support of sepsis.pdf

  261. BulletCurrent Treatment Options for Acute Skin and Skin- structure Infections Review 2019.pdf

  262. BulletCVP Sepsis.pdf

  263. BulletCytokine removal in human septic shock Review 2019.pdf

  264. BulletCytokine removal Rimmele and Pickers.pdf

  265. BulletCytockine storm in a phase 1 trial.pdf

  266. BulletCytokine Storm Review 2020.pdf

  267. BulletCytokine Storms Review 2020.pdf

  268. BulletDaily bathing with chlorhexidine in ICU.pdf

  269. BulletDaptomycin in Combination With Other Antibiotics for the Treatment of Complicated Methicillin-Resistant Staphylococcus aureus Bacteremia.pdf

  270. BulletDe escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.pdf

  271. BulletDe escalation therapy for pneumonia.pdf

  272. BulletDe-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.pdf

  273. BulletDecontamination of Oral or Digestive Tract for Patients in the Intensive Care Unit.pdf

  274. BulletDefining Antibiotic Levels in Intensive care unit patients.pdf

  275. BulletDegradation of albumin in meningococcal sepsis.pdf

  276. BulletDelay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients.pdf

  277. BulletDelaying the Empiric Treatment of Candida Bloodstream Infection.pdf

  278. BulletDengue virus clinical syndromes.pdf

  279. BulletDerivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis Bill Knaus 2019.pdf

  280. BulletDermatological conditions in intensive care ICNARC Database.pdf

  281. BulletDestination of aminoglycoside antibiotics in the ‘post-antibiotic era’.pdf

  282. BulletDetermining the Ideal Strategy for Ventilator-associated Pneumonia Prevention.pdf

  283. BulletDiagnosing VAP 2.pdf

  284. BulletDiagnosing VAP.pdf

  285. BulletDiagnosis and management of respiratory viruses in critically ill adult patients.pdf

  286. BulletDiagnosis and management of skin and soft tissue infections in the intensive care unit Review 2016.pdf

  287. BulletDiagnosis and Treatment of Candidemia in the Intensive Care Unit Review 2019.pdf

  288. BulletDiagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020.pdf

  289. BulletDiagnosis and Treatment of Clostridium difficile in Adults Review 2018.pdf

  290. BulletDiagnosis and treatment of Panton–Valentine leukocidin (PVL)-associated staphylococcal pneumonia.pdf

  291. BulletDiagnosis and treatment of severe sepsis.pdf

  292. BulletDiagnosis and Treatment of VAP Review.pdf

  293. BulletDiagnosis of invasive candidiasis in the ICU review.pdf

  294. BulletDiagnosis of VAP - Edit.pdf

  295. BulletDiagnosis of VAP edit.pdf

  296. BulletDiagnosis of ventilator-associated pneumonia in critically ill Review 2020.pdf

  297. BulletDiagnostic and prognostic biomarkers of sepsis in critical care.pdf

  298. BulletDiagnostic techniques for ventilator-associated pneumonia+ Edit .pdf

  299. BulletDIC and Sepsis.pdf

  300. BulletDifferences in Potency of Intravenous Polyspecific Immunoglobulin G against Streptococcal and Staphylococcal Superantigens.pdf

  301. BulletDifferentiating Culture Samples Representing Coagulase-Negative StaphylococcalBacteremia from Those Representing Contamination by Use of Time-to-Positivity.pdf

  302. BulletDo critical care patients hibernate Mervyn Singer 2019.pdf

  303. BulletDo we need new trials of procalcitonin- guided antibiotic therapy?.pdf

  304. BulletDoctor—your septic patients have scurvy.pdf

  305. BulletDoes Appropriate Antibiotic Therapy Mean Only Adequate Spectrum and Timing.pdf

  306. BulletDoes aspirin use prevent acute coronary syndrome in patients with pneumonia.pdf

  307. BulletDoes Augmented Creatinine Clearance Accurately Reflect Glomerular Hyperfiltration in Critical Illness.pdf

  308. BulletDoes this patient have VAP?.pdf

  309. BulletDoes ventilator-associated event surveillance detect ventilator-associated pneumonia in intensive care units.pdf

  310. BulletDose adjustments for antimicrobial therapy in very obese patients.pdf

  311. BulletDuration of hypotension before starting antibiotics determines outcome in septic shock.pdf

  312. BulletDysbiosis in the ICU Microbiome science coming to the bedside.pdf

  313. BulletEarly Administration of Antibiotics for Suspected Sepsis.pdf

  314. BulletEarly Antibiotic Discontinuation in Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative Bronchoscopy Cultures.pdf

  315. BulletEarly Chest Computed Tomography Scan to Assist Diagnosis and Guide Treatment Decision for Suspected Community-acquired Pneumonia.pdf

  316. BulletEarly identification of patients at high risk of group A streptococcus-associated necrotizing skin and soft tissue infections.pdf

  317. BulletEarly peak temperature and prognosis in ITU.pdf

  318. BulletECDC Surveillance report 2017.pdf

  319. BulletEchinocandins review.pdf

  320. BulletEchinocandins.pdf

  321. BulletEffect of Aerosolized Colistin on Gram-Negative Bacteria.pdf

  322. BulletEffect of Combined β-Lactam : Macrolide Therapy on Mortality According to the Microbial Aetiology and Inflammatory Status of Patients with Community - Acquired Pneumonia 2018.pdf

  323. BulletEffect of Daily Chlorhexidine Bathing on Hospital-Acquired Infection.pdf

  324. BulletEffect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients.pdf

  325. BulletEffect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients.pdf

  326. BulletEffect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis Review 2018.pdf

  327. BulletEffect of selective decontamination on antimicrobial resistance in intensive care units.pdf

  328. BulletEffect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level.pdf

  329. BulletEffect of Thiamine Administration on Lactate Clearance and Mortality in Patients With Septic Shock.pdf

  330. BulletEffect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure.pdf

  331. BulletEffective Treatment of Clostridium difficile Infection.pdf

  332. BulletEffectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections.pdf

  333. BulletEffects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs.pdf

  334. BulletEffects of different antibiotic classes on airway bacteria in stable COPD.pdf

  335. BulletEffects of endotoxin on lactate metabolism in humans.pdf

  1. BulletEfficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients.pdf

  2. BulletEfficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients.pdf

  3. BulletEfficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection.pdf

  4. BulletEmergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care Patients.pdf

  5. BulletEmpiric antibiotic therapy for suspected ventilator-associated pneumonia Review.pdf

  6. BulletEmpiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour.pdf

  7. BulletEmpiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis.pdf

  8. BulletEmpiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.PDF

  9. BulletEmpirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia.pdf

  10. BulletEndotracheal tube associated pneumonia review.pdf

  11. BulletEndotracheal Tubes-infections Edit.pdf

  12. BulletEnhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile.pdf

  13. BulletEPIC III.pdf

  14. BulletEPIC ll.pdf

  15. BulletEpidemic of carbapenem-resistant Klebsiella  pneumoniae in Europe is driven by nosocomial  spread.pdf

  16. BulletEpidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an intensive care unit with no single rooms.pdf

  17. BulletEpidemiology of ICU-acquired pneumonia Review 2018.pdf

  18. BulletEpidemiology of intra-abdominal infection and sepsis in critically ill patients.pdf

  19. BulletEpidemiology of Invasive Group B Streptococcal Infections.pdf

  20. BulletEpidemiology of sepsis.pdf

  21. BulletESBL Enterobacteriaceae Review.pdf

  22. BulletESBL genes in chicken and humans.pdf

  23. BulletEscherichia coli O157 review.pdf

  24. BulletEstimating Ten-Year Trends in Septic Shock Incidence and Mortality in United States.pdf

  25. BulletEuropean surveillance of healthcare-associated-infections-HAI-ICU-protocol.pdf

  26. BulletEvaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae .pdf

  27. BulletEvaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms.pdf

  28. BulletEvaluation of the effect of diagnostic methodology on the reported incidence of ventilator-associated pneumonia.pdf

  29. BulletEvidence is stronger than you think a meta-analysis of vitamin C use in patients with sepsis.pdf

  30. BulletEvidence of macrolides for severe CAP.pdf

  31. BulletExcluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms.pdf

  32. BulletExtended-Infusion Piperacillin-Tazobactam Study.pdf

  33. BulletExtracorporeal Blood Purification Therapies for Sepsis Review 2019.pdf

  34. BulletExtracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy Review.pdf

  35. BulletExtreme Dysbiosis of the Microbiome in Critical Illness.pdf

  36. BulletFacing COVID-19 in the ICU vascular dysfunction, thrombosis, and dysregulated inflammation.pdf

  37. BulletFactors associated with septic shock and mortality in generalized peritonitis.pdf

  38. BulletFactors Predicting Mortality in Necrotizing Community-Acquired Pneumonia Caused by Staphylococcus aureus Containing Panton-Valentine Leukocidin.pdf

  39. BulletFaecal peritonitis admitted to ITU GenoSept.pdf

  40. BulletFaecal volatile biomarkers of Clostridium difficile infection.pdf

  41. BulletFailure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors.pdf

  42. BulletFecal Colonization With Extended-spectrum Beta-lactamase–Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals.pdf

  43. BulletFecal Microbiota Transplantation and Successful Resolution of Multidrug-Resistant-Organism Colonization.pdf

  44. BulletFever control.pdf

  45. BulletFever in septic ICU patients friend or foe? Review 2012.pdf

  46. BulletFever management in intensive care patients with infections review 2014.pdf

  47. BulletFever in the critically ill Review.pdf

  48. BulletFever in the ITU Review 2016.pdf

  49. BulletFinding source of sepsis in ICU Review.pdf

  50. BulletFirst-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients.pdf

  51. BulletFocus on adequate antimicrobial treatment and de-escalation in the ICU.pdf

  52. BulletFocus on optimization of early antimicrobial therapy in ICU-acquired infections.pdf

  53. BulletFocus on sepsis 2019.pdf

  54. BulletFrench guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU 2018.pdf

  55. BulletFundamentals of aerosol therapy in critical care Review 2016.pdf

  56. BulletFungal infections in the ICU Review 2015.pdf

  57. BulletGalactomannan in BAL diagnosis of aspergillosis.pdf

  58. BulletGalactomannan testing of BAL fluid for diagnosis of invasive pulmonary aspergillosis.pdf

  59. BulletGalactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis.pdf

  60. BulletGenome-wide association study of survival from sepsis due to pneumonia.pdf

  61. BulletGlobal warming “heating up” the ICU through Candida auris infections.pdf

  62. BulletGlucocorticoid treatment in community-acquired pneumonia.pdf

  63. BulletGlucocorticoids and invasive fungal infections.pdf

  64. BulletGlucocorticoids in sepsis 2011.pdf

  65. BulletGram-positive bacterial superantigen outside-in signaling causes toxic shock syndrome.pdf

  66. BulletGram-positive toxic shock syndromes Review.pdf

  67. BulletGuidance on the diagnosis and management of PVL–associated Staphylococcus aureus infections in the UK.pdf

  68. BulletGuide to Diagnosis of Infectious Diseases 2013.pdf

  69. BulletGuidelines for hospital-acquired pneumonia and health-care-associated pneumonia edit.pdf

  70. BulletGut Bacteria Are Linked to Success of Cancer Treatment.pdf

  71. BulletGut integrity in critical illness Review 2019 (Coopersmith).pdf

  72. BulletGut Microbiome of an 11th Century A.D. Pre- Columbian Andean Mummy.pdf

  73. BulletH1N1 and ICU occupancy in Australia and NZ.pdf

  74. BulletH1N1 pneumonitis treated with intravenous zanamivir .pdf

  75. BulletH1N1 Viral infection Clinical Aspects.pdf

  76. BulletHaemoperfusion with polymyxin B membrane 2019.pdf

  77. BulletHandshake-ban-to-curb-hospital-infections.pdf

  78. BulletHealthcare-associated bloodstream infections in critically ill patients.pdf

  79. BulletHematologic Effects of Linezolid.pdf

  80. BulletHemoadsorption therapy in the critically ill.pdf

  81. BulletHemoadsorption with CytoSorb shows a decreased observed versus expected 28- day all-cause mortality in ICU patients with septic shock.pdf

  82. BulletHemoadsorption with CytoSorb.pdf

  83. BulletHepatotoxicity of Antifungals in Invasive Fungal Infection Review.pdf

  84. BulletHerpes simplex encephalitis the pitfall of multiple false-negative polymerase chain reactions.pdf

  85. BulletHerpes simplex encephalitis.pdf

  86. BulletHigh Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics.pdf

  87. BulletHigh toxin producing Clostridium difficile.pdf

  88. BulletHigh-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients letter.pdf

  89. BulletHigher than recommended amikacin loading doses achieve targets without toxicity.pdf

  90. BulletHospital acquired guidelines European experience.pdf

  91. BulletHospital-Acquired Infections Due to Gram-Negative Bacteria.pdf

  92. BulletHospital-Acquired Pneumonia Review Seminar 2017.pdf

  93. BulletHot topics and current controversies in community acquired pneumonia Review 2019.pdf

  94. BulletHow best to determine causative pathogens of pneumonia.pdf

  95. BulletHow long do nosocomial pathogens persist on inanimate surfaces? Review.pdf

  96. BulletHow to manage aspergillosis in non-neutropenic intensive care unit patients review 2014.pdf

  97. BulletHow to manage severe dengue infection.pdf

  98. BulletHydrocortisone and Ascorbic Acid Synergistically Prevent and Repair Lipopolysaccharide Induced Pulmonary Endothelial Barrier Dysfunction.pdf

  99. BulletHydrocortisone plus Fludrocortisone for Adults with Septic Shock 2018.pdf

  100. BulletICU 06 HIV.pdf

  101. BulletICU Acquisition Rate, Risk Factors, and Clinical Signi cance of Digestive Tract Colonization With Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae Review 2017.pdf

  102. BulletICU fungal infection.pdf

  103. BulletIdentifying “at-risk” patients for sub-optimal beta-lactam exposure in critically ill patients.pdf

  104. BulletImmunomodulation by macrolides therapeutic potential for critical care Review 2020.pdf

  105. BulletImmunosuppression in Patients Who Die of Sepsis.pdf

  106. Bullet Immunosuppression in Patients Who Die of Sepsis.pdf

  107. BulletImpact of 30 mg:kg amikacin and 8 mg:kg gentamicin on serum concentrations in critically ill patients with severe sepsis.pdf

  108. BulletImpact of antibiotic administration on blood culture positivity at the beginning of sepsis.pdf

  109. BulletImpact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia.pdf

  110. BulletImpact of compliance with infection management guidelines on outcome.pdf

  111. BulletImpact of Diagnostic Criteria on the Incidence of Ventilator-Associated Pneumonia.pdf

  112. BulletImpact of hemoperfusion with polymyxin B added to hemofiltration in patients with endotoxic shock 2019.pdf

  113. BulletImpact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia.pdf

  114. BulletImpact of previous antibiotic therapy on outcome of Gram-negative severe sepsis.pdf

  115. BulletImpact of Source Control in Patients With Severe Sepsis and Septic Shock.pdf

  116. BulletImpact of species and antibiotic therapy of enterococcal peritonitis on 30-day mortality in critical care 2019.pdf

  117. BulletImpaired mitochondria in septic shock.pdf

  118. BulletImplementation of earlier antibiotic administration in patients with severe sepsis and septic shock in Japan.pdf

  119. BulletImplementation of guidelines for HAPneumonia.pdf

  120. BulletImportance of Viral Pathogens in Nonventilated Hospital-Acquired Pneumonia.pdf

  121. BulletIn Treating Sepsis, Questions About Timing and Mandates.pdf

  122. BulletInadequate Antimicrobial Treatment of Infections.pdf

  123. BulletInappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock.pdf

  124. BulletIncidence and mortality of hospital- and ICU-treated sepsis 2020.pdf

  125. BulletIncidence and Outcomes Associated With Clostridium difficile Infections 2020.pdf

  126. BulletIncidence and prognosis of ventilator-associated tracheobronchitis.pdf

  127. BulletIncreasing Incidence of and Increased Mortality Associated With Clostridium difficile–Associated Megacolon.pdf

  128. BulletIndividualised antibiotic dosing for patients who are critically ill review 2014.pdf

  129. BulletIndividuals with obesity and COVID-19 Review 2020.pdf

  130. BulletInfection in the critically ill.pdf

  131. BulletIndividualizing Risk of Multidrug-Resistant Pathogens in Community-Onset Pneumonia.pdf

  132. BulletInfection in Transplantation.pdf

  133. BulletInfections IARS Review course 2006.pdf

  134. BulletInfectious diseases the 10 common truths I never believed.pdf

  135. BulletInfective endocarditis adjunct diagnostic methods 2019.pdf

  136. BulletInflammatory Markers at Hospital Discharge Predict Subsequent Mortality after Pneumonia and Sepsis.pdf

  137. BulletInfluenza and ARDS.pdf

  138. BulletInfluenza in ICU Review.pdf

  139. BulletInfluenza Pneumonia Diagnosed on Reverse Transcription-polymerase Chain Reaction(RT-PCR) of Bronchoalveolar Lavage Fluid but not Rapid Tests with Nasopharyngeal Swabs.pdf

  140. BulletInfluenza virus-related critical illness Review 2 2019.pdf

  141. BulletInfluenza virus-related critical illness Review 2019.pdf

  142. BulletInfluenza-associated Aspergillosis in Critically Ill Patients.pdf

  143. BulletInhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia .pdf

  144. BulletInitial use of one or two antibiotics for critically ill patients with community-acquired pneumonia.pdf

  145. BulletInsights Into the Mechanism of Aminoglycoside Nephrotoxicity.pdf

  146. BulletInsufficient beta lactam concentrations in the early phase of severe sepsis.pdf

  147. BulletIntensive Care of Patients with HIV Infection.pdf

  148. BulletIntensive care unit management of intra-abdominal infection.pdf

  149. BulletIntrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia.pdf

  150. Bulletintravenous immunoglobulin for the treatment of severe sepsis Review.pdf

  151. BulletInvasive and non-invasive diagnostic approaches for microbiological diagnosis of hospital-acquired pneumonia.pdf

  152. BulletInvasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia.pdf

  153. BulletInvasive aspergillosis in critically ill patients An autopsy study 2019.pdf

  154. BulletInvasive aspergillosis in patients admitted to the intensive care unit with severe influenza.pdf

  155. BulletInvasive candidiasis as a cause of sepsis in the critically ill patient Review 2014.pdf

  156. BulletInvasive Candidiasis Review 2015.pdf

  157. BulletInvasive candidiasis review.pdf

  158. BulletInvasive Candidiasis.pdf

  159. BulletInvasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia.pdf

  160. BulletInvasive pulmonary aspergillosis in cirrhotic patients.pdf

  161. BulletIs a “Cytokine Storm” Relevant to COVID-19?.pdf

  162. BulletIs Bacteremic Sepsis Associated With Higher Mortality in Transplant Recipients Than in Nontransplant Patients.pdf

  163. BulletIs MOF an outcome parameter or a transient, adaptive state in critical illness?.pdf

  164. BulletIs nosocomial infection really the major cause of death in sepsis.pdf

  165. BulletIs patient isolation the single most important measure to prevent the spread of multidrug-resistant pathogens?.pdf

  166. BulletIs prolonged infusion of piperacillin:tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic: pharmacodynamic and patient outcomes.pdf

  167. BulletIt’s not just the antibiotics, it’s the treatment.pdf

  168. BulletL-lactic acidosis Review 2019.pdf

  169. BulletLaboratory Diagnosis of Central Nervous System Infection.pdf

  170. BulletLack of Benefit of High-Dose Vitamin C, Thiamine, and Hydrocortisone Combination for Patients With Sepsis 2020.pdf

  171. BulletLactate in the critically ill patients edit.pdf

  172. BulletLactate kinetics in sepsis and septic shock.pdf

  173. BulletLactate.pdf

  174. BulletLactic acidosis in sepsis  It’s not all anaerobic. Implications for diagnosis and management.pdf

  175. BulletLegionnaires’ disease Review 2015.pdf

  176. BulletLeptospirosis 2019.pdf

  177. BulletLeptospirosis today a rare occurrence, in the future more prevalent.pdf

  178. BulletLess contact isolation is more in the ICU.pdf

  179. BulletLeveraging the Laboratory to Improve Antimicrobial Use.pdf

  180. BulletLikelihood of infection in patients with presumed sepsis at the time of intensive care unit admission.pdf

  181. BulletLinezolid Review 2018.pdf

  182. BulletLinezolid versus vancomycin or teicoplanin for nosocomial pneumonia.pdf

  183. BulletLinezolid vs Daptomycin for Vancomycin-Resistant Enterococci.pdf

  184. BulletLinezolid vs Vancomycin.pdf

  185. BulletLong-term impact of sepsis on cardiovascular health 2018.pdf

  186. BulletLong-term outcome of severe herpes simplex encephalitis.pdf

  187. BulletLumbar Puncture Performed Promptly or After Neuroimaging in Acute Bacterial Meningitis.pdf

  188. BulletMacrolide Antibiotics and the Risk of Cardiac Arrhythmias.pdf

  189. BulletMacrolide Lung inflammatory pattern and antibiotic treatment in pneumonia.pdf

  190. BulletMacrolides and community acquired pneumonia is quorum sensing the key.pdf

  191. BulletMacrolides and Mortality in Critically Ill Patients With Community-Acquired Pneumonia review 2014.pdf

  192. BulletMacrolides and steroids in CAP.pdf

  193. BulletMacrolides on the production of pneumolysin by Streptococcus pneumoniae.pdf

  194. BulletManagement of Adults With Hospital-acquired and Ventilator-associated Pneumonia Guidelines 2016.pdf

  195. BulletManagement of AIDS-Related Pneumothorax.pdf

  196. BulletManagement of hemodialysis catheter related bacteremia with an adjunctive antibiotic lock solution.pdf

  197. BulletManagement of necrotizing pneumonia and pulmonary gangrene Review.pdf

  198. BulletManagement of pneumonia in ITU Review 2018.pdf

  199. BulletManagement of Sepsis.pdf

  200. BulletManagement of septic shock and severe infections in migrants and returning travelers requiring critical care.pdf

  201. BulletManagement of Severe Sepsis controversies Marik Review 2014.pdf

  202. BulletManaging Invasive Fungal Infections.pdf

  203. BulletManaging malaria in the intensive care unit Review.pdf

  204. BulletManipulating vital signs in septic shock.pdf

  205. BulletMeasuring bacterial load and virulence factors.pdf

  206. BulletMechanical influences on fluid leakage past the tracheal tube cuff.pdf

  207. BulletMechanism of Macrolide-Induced Inhibition of Pneumolysin Release Involves Impairment of Autolysin Release in Macrolide-Resistant Streptococcus pneumoniae.pdf

  208. BulletMechanisms of antimicrobial resistance in Gram-negative bacilli Review 2015.pdf

  209. BulletMechanisms of Cardiac and Renal Dysfunction in Patients Dying of Sepsis.pdf

  210. BulletMeningitis and encephalitis management in the ICU Review 2019.pdf

  211. Bulletmeningococcal disease review.pdf

  212. BulletMeropenem and piperacillin:tazobactam prescribing using extended infusions.pdf

  213. BulletMeropenem dosage.pdf

  214. BulletMeropenem review.pdf

  215. Bulletmetabolic failure review.pdf

  216. BulletMIC of vancomycin and clinical outcome.pdf

  217. BulletMicro organism in Septic Shock.pdf

  218. BulletMicrovascular and macrovascular flow are uncoupled in early polymicrobial sepsis.pdf

  219. BulletMitochondria and Critical Illness Review 2019.pdf

  220. BulletMitochondria in Sepsis review.pdf

  221. BulletMitochondrial Failure in sepsis.pdf

  222. BulletMultidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis.pdf

  223. BulletMultidrug resistant bacteria in critically ill patients Review 2018.pdf

  224. BulletMultidrug resistant pathogens - alternatives to new antibiotics? Review 2017.pdf

  225. BulletMycobacterium tuberculosis Septic Shock.pdf

  226. BulletNative-Valve Infective Endocarditis 2020.pdf

  227. BulletNatural history and decolonization strategies for ESBL:carbapenem-resistant Enterobacteriaceae carriage.pdf

  228. BulletNebulized Antibiotics 2019.pdf

  229. BulletNebulized colistin for the treatment of nosocomial pneumonia.pdf

  230. BulletNebulized Colistin in the Treatment of Pneumonia Due to Multidrug- Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.pdf

  231. BulletNebulized Colistin in Ventilator- associated Pneumonia.pdf

  232. BulletNecrotising fasciitis.pdf

  233. BulletNecrotizing Fasciitis and Deep Soft Tissue Infections in the ICU | The American College of Chest Physicians.pdf

  234. BulletNecrotizing fasciitis review 2012.pdf

  235. BulletNecrotizing Fasciitis.pdf

  236. BulletNecrotizing soft tissue infections in the intensive care unit Review.pdf

  237. BulletNecrotizing soft tissue infections Review.pdf

  238. BulletNecrotizing soft tissue infections.pdf

  239. BulletNecrotizing Soft-Tissue Infection Review.pdf

  240. BulletNecrotizing Soft-Tissue Infections Review 2017.pdf

  241. BulletNeglected Variables in the Interpretation of Serum Procalcitonin Levels in Patients With Septic Shock 2020.pdf

  242. BulletNeutralization of Staphylococcus aureus Panton Valentine Leukocidin by Intravenous Immunoglobulin In Vitro.pdf

  243. BulletNeutrophils in MODS.pdf

  244. BulletNew antibiotics for intra abdominal infections.pdf

  245. BulletNew aspects in the management of pneumonia 2016.pdf

  246. BulletNew concepts and findings in sepsis care 2018.pdf

  247. BulletNew Definitions for Sepsis and Septic Shock (Sepsis-3) 2016.pdf

  248. BulletNew Delhi Metallo-β-Lactamase–Producing Carbapenem-Resistant Escherichia coli.pdf

  249. BulletNew insights into the gut as the driver of critical illness and organ failure.pdf

  250. BulletNew Sepsis Criteria A Change We Should Not Make.pdf

  251. BulletNew Therapies for Pneumonia.pdf

  252. BulletNon bronchoscopic BAL.pdf

  253. BulletNon-infectious mimics of community- acquired pneumonia.pdf

  254. BulletNonsteroidal Antiinflammatory Drugs May Affect the Presentation and Course of Community-Acquired Pneumonia.pdf

  255. BulletNoradrenaline drives immunosuppression in sepsis 2020.pdf

  256. BulletNosocomial candida infections review.pdf

  257. BulletNosocomial infections and ICU patients review.pdf

  258. BulletNosocomial Pneumonia.pdf

  259. BulletNot all β-lactams are equal regarding neurotoxicity.pdf

  260. BulletNovel Therapies for Septic Shock Over the Past 4 Decades.pdf

  261. BulletOn the origins of lactate during sepsis.pdf

  262. BulletOnset and Duration of Urinary Antigen Excretion in Legionnaires Disease.pdf

  263. BulletOptimal practices to prevent, recognize, and manage complications associated with intravascular devices in the critically ill Review 2018.pdf

  264. BulletOptimization of linezolid therapy in the critically ill.pdf

  265. BulletOptimizing Antimicrobial Therapy of Sepsis and Septic Shock.pdf

  266. BulletOptimizing therapy of bloodstream infection due to extended-spectrum b-lactamase-producing Enterobacteriaceae Review 2019.pdf

  267. BulletOropharyngeal Bacterial Colonization after Chlorhexidine Mouthwash in Mechanically Ventilated Critically Ill Patients.pdf

  268. BulletOutbreak of a new coronavirus what anaesthetists should know.pdf

  269. BulletOutcome of Immediate Versus Early Antibiotics in Severe Sepsis and Septic Shock Review 2020.pdf

  270. BulletOutcome of Vancomycin Treatment in Patients with Methicillin-Susceptible Staphylococcus aureus Bacteremia.pdf

  271. BulletOutcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia.pdf

  272. BulletOutcomes in Patients With Severe West Nile.pdf.pdf

  273. BulletOutcomes of patients undergoing early sepsis resuscitation for cryptic shock compared with overt shock.pdf

  274. BulletOutcomes of β-Hemolytic Streptococcal Necrotizing Skin and Soft-tissue Infections and the Impact of Clindamycin Resistance.pdf

  275. BulletOverdiagnosis of Clostridium difficile Infection in the Molecular Test Era.pdf

  276. BulletOXA-48-Type Carbapenemases Review 2019.pdf

  277. BulletPanton–Valentine leukocidin-positive Staphylococcus aureus Review 2018.pdf

  278. BulletPassive Immunity in Prevention and Treatment of Infectious Diseases.pdf

  279. BulletPathogen species and infection sites are not associated with mortality.pdf

  280. BulletPathogenesis of staph aureus necrotizing pneumonia.pdf

  281. BulletPathophysiology and treatment of sepsis.pdf

  282. BulletPathophysiology of endotoxic shock.pdf

  283. BulletPatients with community acquired pneumonia admitted to European intensive care units GenOSept.pdf

  284. BulletPCR diagnosis in sepsis Review.pdf

  285. BulletPCR in microbiological testing for sepsis.pdf

  286. BulletPCT v CRP over time.pdf

  287. BulletPenetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia.pdf

  288. BulletPersistence of Streptococcus pneumoniae urinary antigen excretion after pneumococcal pneumonia.pdf

  289. BulletPenetration of vancomycin into human lung tissue.pdf

  290. BulletPenicillin Allergy Review 2019.pdf

  291. BulletPerformance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia.pdf

  292. BulletPersistent Fever in the ICU.pdf

  293. BulletPersistent lung inflammation after clinical resolution of community-acquired pneumonia as measured by 18FDG-PET:CT.pdf

  294. BulletPersonalized CHF treatment PCT to guide therapy in heart failure patients.pdf

  295. BulletPET-CT for detecting the undetected in the ICU.pdf

  296. BulletPET:CT for Detection of Metastatic Infection in Gram-Positive Bacteremia.pdf

  297. BulletPharmacodynamics of Gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.pdf

  298. BulletPharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient.pdf

  299. BulletPharmacokinetic dosing of aminoglycosides.pdf

  300. BulletPharmacokinetic rationale for antibiotic dosing.pdf

  301. BulletPharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.pdf

  302. BulletPharmacokinetics and pharmacodynamics of piperacillin by continuous infusion v bolus.pdf

  303. BulletPharmacokinetics of Amikacin in ITU.pdf

  304. BulletPharmacokinetics of antibiotics in ICU Review.pdf

  305. BulletPharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration.pdf

  306. BulletPiperacillin Tazobactem Review.pdf

  307. BulletPiperacillin-Tazobactam infusion for Pseudomonas aeruginosa Infection.pdf

  308. BulletPiperacillin–tazobactam as alternative to carbapenems for ICU patients.pdf

  309. BulletPIRO Model Review 2014.pdf

  310. BulletPneumonia as a cardiovascular disease 2018.pdf

  311. BulletPolymicrobial community-acquired pneumonia.pdf

  312. BulletPolymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia.pdf

  313. BulletPolymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis:septic shock.pdf

  314. BulletPost-operative abdominal infections Review 2019.pdf

  315. BulletPotential false-positive urine Legionella enzyme immunoassay test results.pdf

  316. BulletPotential Strategies to Prevent Ventilator-Associated Events.pdf

  317. BulletPotential survival benefit of polymyxin B hemoperfusion in patients with septic shock.pdf

  318. BulletPre-emptive antibiotic therapy to reduce ventilator-associated pneumonia.pdf

  319. BulletPredictive Value of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Swab PCR Assay for MRSA Pneumonia.pdf

  320. BulletPredictors of mortality among bacteremic patients with septic shock receiving appropriate antimicrobial therapy.pdf

  321. BulletPrevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017 EPIC III.pdf

  322. BulletPrevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality 2019.pdf

  323. BulletPreventing Central Line-Associated Bloodstream Infections.pdf

  324. BulletPrevention of Catheter-related Bloodstream Infection in Patients on Hemodialysis.pdf

  325. BulletPrevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest 2019.pdf

  326. BulletPrevention of overwhelming sepsis in asplenic patients.pdf

  327. BulletPrevention of VAP review 2.pdf

  328. BulletPrevention of VAP Review.pdf

  329. BulletPrevention of Ventilator Associated Pneumonia.pdf

  330. BulletPrevention of ventilator-associated pneumonia or ventilator-associated complications review.pdf

  331. BulletPreventive and therapeutic strategiesin critically ill patients with highly resistant bacteria.pdf.pdf

  332. BulletPrevious intratracheal aspiration to detect cause of VAP.pdf

  333. BulletProbiotics in the critically ill review 2012.pdf

  334. BulletProcalcitonin (PCT) in patients with abdominal sepsis.pdf

  335. BulletProcalcitonin (PCT)-guided antibiotic stewardship Review 2019.pdf

  336. BulletProcalcitonin Algorithm in Critically Ill Adults with Undifferentiated Infection or Suspected Sepsis.pdf

  337. BulletProcalcitonin and antibiotic use imperfect, yet effective.pdf

  338. BulletProcalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection Review.pdf

  339. BulletProcalcitonin as a diagnostic marker for sepsis review 2013.pdf

  1. BulletProcalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma Review.pdf

  2. BulletProcalcitonin for reduced antibiotic exposure in the critical care review.pdf

  3. BulletProcalcitonin Impairs Endothelial Cell Function and Viability.pdf

  4. BulletProcalcitonin in acute infections Review 2019.pdf

  5. BulletProcalcitonin in critically ill patients.pdf

  6. BulletProcalcitonin in predicting infected necrotising pancreatitis and prognosis.pdf

  7. BulletProcalcitonin in predicting infected necrotising pancreatitis.pdf

  8. BulletProcalcitonin in Severe Community-Acquired Pneumonia.pdf

  9. BulletProcalcitonin is an essential biomarker for hydrocortisone, ascorbic acid, and thiamine (HAT) therapy in patients with sepsis Marik.pdf

  10. BulletProcalcitonin kinetics.pdf

  11. BulletProcalcitonin kinetics after burn injury and burn surgery in septic and non-septic patients.pdf

  12. BulletProcalcitonin levels in bloodstream infections caused by different sources and species of bacteria.pdf

  13. BulletProcalcitonin levels in candidemia versus bacteremia Review 2019.pdf

  14. BulletProcalcitonin ratio as a predictor of successful surgical treatment of severe necrotizing soft tissue infections.pdf

  15. BulletProcalcitonin review 2010:11.pdf

  16. BulletProcalcitonin Review 2016.pdf

  17. BulletProcalcitonin review.pdf

  18. BulletProcalcitonin The right answer but to which question?.pdf

  19. BulletProcalcitonin to allow early detection of sepsis and multiple organ failure in severe multiple trauma.pdf

  20. BulletProcalcitonin to guide antibiotics.pdf

  21. BulletProcalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections Cochrane Review 2017.pdf

  22. BulletProcalcitonin to reduce antibiotics in ICU (Prorata trial).pdf

  23. BulletProcalcitonin-guided antibiotic stewardship from newborns to centennials.pdf

  24. BulletProcalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis.pdf

  25. BulletProcalcitonin-guided diagnosis and antibiotic stewardship revisited 2017.pdf

  26. BulletProcalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection.pdf

  27. BulletPrognostic and diagnostic value of eosinopenia, C reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis.pdf

  28. BulletPrognostic factors for mortality in fecal peritonitis.pdf

  29. BulletProlonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis Review 2017.pdf

  30. BulletProlonging culture to 15 days improves bacterial detection in bone and joint infections.pdf

  31. BulletProphylactic Antimicrobial Therapy for Acute Aspiration Pneumonitis.pdf

  32. BulletPros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics.pdf

  33. BulletProtracted immune disorders at one year after ICU discharge in patients with septic shock.pdf

  34. BulletPseudomonas aeruginosa serotypes in nosocomial pneumonia.pdf

  35. BulletPseudomonas aeruginosa type III secretion Review 2014.pdf

  36. BulletPseudomonas Pathology WKronish.pdf

  37. BulletPseudomonas review.pdf

  38. BulletPVL Factors Predicting Mortality in Necrotizing Community-Acquired Pneumonia.pdf

  39. BulletPVL Impact of Antibiotics on Expression of Virulence- Associated Exotoxin.pdf

  40. BulletPVL Staph pneumonia.pdf

  41. BulletPVL Staphylococcus aureus strains and highly lethal necrotising pneumonia.pdf

  42. BulletqSOFA does not replace SIRS in the definition of sepsis.pdf

  43. BulletRaising concerns about the Sepsis-3 definitions.pdf

  44. BulletRaising concerns about the Sepsis-3 definitions.pdf

  45. BulletRandomized non-inferiority trial to compare trimethoprim:sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection.pdf

  46. BulletRapid Diagnosis of Infection in the Critically Ill, a Multicenter Study of Molecular Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections.pdf

  47. BulletRate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia.pdf

  48. BulletReceipt of Antibiotics in Hospitalized Patients and Risk for Clostridium difficile Infection in Subsequent Patients Who Occupy the Same Bed.pdf

  49. BulletRecent advances in understanding and managing sepsis 2018.pdf

  50. BulletRecognition and prevention of nosocomial invasive fungal infections in the intensive care unit.pdf

  51. BulletRecognizing Sepsis as a Global Health Priority —A WHO Resolution.pdf

  52. BulletRecommended beta lactam dosing inadequate in septic patients on RRT.pdf

  53. BulletReconsidering critical illness as an uncharacterised acquired mitochondrial disorder.pdf

  54. BulletReconsidering Isolation Precautions for Endemic Methicillin-Resistant Staphylococcus aureus and Vancomycin Resistant Enterococcus.pdf

  55. BulletReducing mortality in sepsis review.pdf

  56. BulletReduction of Bacterial Resistance with Inhaled Antibiotics in the Intensive Care Unit.pdf

  57. BulletRelation between presence of extended-spectrum β-lactamase-producing Enterobacteriaceae in systematic rectal swabs and respiratory tract specimens.pdf

  58. BulletRemoval of Humoral Mediators and the Effect on the Survival of Septic Patients by Hemoperfusion With Neutral Microporous Resin Column.pdf

  59. BulletRenal toxicity associated with continuous infusion of vancomycin in critically ill patients.pdf

  60. BulletRepeating blood cultures after initial bacteremia.pdf

  61. BulletResolution of Infectious Parameters after Antimicrobial Therapy in Patients with Ventilator-associated Pneumonia.pdf

  62. BulletRethinking Contact Isolation for Multidrug-Resistant Organisms.pdf

  63. BulletRethinking the concepts of community-acquired and health-care-associated pneumonia.pdf

  64. BulletReversing mitochondrial dysfunction review.pdf

  65. BulletReview and Meta-Analysis of Linezolid and Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bloodstream Infections.pdf

  66. BulletRevisiting the loading dose of amikacin.pdf

  67. BulletRifampicin for Staphylococcus aureus bacteraemia.pdf

  68. BulletRisk factors and Predictors of Mortality in Streptococcal Necrotizing Soft-Tissue Infections 2020.pdf

  69. BulletRisk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia.pdf

  70. BulletRisk Factors for Drug-Resistant Pathogens in Community-acquired and Healthcare-associated Pneumonia.pdf

  71. BulletRisk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis.pdf

  72. BulletRisk factors for target non-attainment during empirical treatment with b-lactam antibiotics in critically ill patients.pdf

  73. BulletRisk of Acute Kidney Injury in Patients on Vancomycin and Piperacillin–Tazobactam.pdf

  74. BulletRisk of organism acquisition from prior room occupants.pdf

  75. BulletRisks for multidrug-resistant pathogens in the ICU Review 2014.pdf

  76. BulletRole of biomarkers in the management of antibiotic therapy.pdf

  77. BulletRole of Procalcitonin in the Management of Infected Patients in the Intensive Care Unit Review.pdf

  78. BulletRole of procalcitonin use in the management of sepsis Review 2020.pdf

  79. BulletRole of the adaptive immune response in sepsis Review 2020.pdf

  80. BulletRole of the microbiome, probiotics, and ‘dysbiosis therapy’ in critical illness.pdf

  81. BulletRoute of transmission of Staphylococcus aureus in the ITU.pdf

  82. BulletSafety and accuracy of mini BAL in suspected VAP.pdf

  83. BulletSafety of vitamin C in sepsis.pdf

  84. BulletSaving Lives With Optimal Antimicrobial Chemotherapy.pdf

  85. BulletSDD and Oropharyngeal decontamination.pdf

  86. BulletSDD Edit.pdf

  87. BulletSDD in critically ill patients.pdf

  88. BulletSDD Why not.pdf

  89. BulletSeasonal influenza ICS guidance for adult critical care units 2017.pdf

  90. BulletSecondary peritonitis Review 2018.pdf

  91. BulletSelective decontamination and antibiotic resistance in ICUs Review 2015.pdf

  92. BulletSensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia.pdf

  93. BulletSepsis and Endothelial Permeability Review.pdf

  94. BulletSepsis and septic shock Review 2018.pdf

  95. BulletSepsis and the heart review.pdf

  96. BulletSepsis biomarkers review.pdf

  97. BulletSepsis Biomarkers.pdf

  98. BulletSepsis caused by Elizabethkingia miricola.pdf

  99. BulletSepsis definitions.pdf

  100. BulletSepsis hysteria Mervyn Singer 2019.pdf

  101. BulletSepsis in Intensive Care Unit Patients - ICON.pdf

  102. BulletSepsis in the ICU ICON .pdf

  103. BulletSepsis pathophysiology and clinical management Review 2016.pdf

  104. BulletSepsis Perspective 2020.pdf

  105. BulletSepsis-associated hyperlactatemia review 2014.pdf

  106. BulletSeptic Shock and Inappropriate Antibiotic Therapy.pdf

  107. BulletSeptic shock from community- onset pneumonia role for aspirin and macrolides.pdf

  108. BulletSeptic shock review.pdf

  109. BulletSeptic shock Review 2015.pdf

  110. BulletSeptic shock with no diagnosis at 24 hours.pdf

  111. BulletSerratia Marcescens- They Make Holy Statues "Bleed"--and Can Be Deadly, Too.pdf

  112. BulletSerum Procalcitonin and Proinflammatory Cytokines in a Patient with Acute Severe Leptospirosis.pdf

  113. BulletSerum procalcitonin and the admission decision in CAP.pdf

  114. BulletSerum Procalcitonin for Discrimination of Blood Contamination from Bloodstream Infection due to Coagulase-Negative Staphylococci.pdf

  115. BulletSevere atypical pneumonia in critically ill patients.pdf

  116. BulletSevere Community-Acquired Pneumonia and PIRO.pdf

  117. BulletSevere community-acquired pneumonia demographics, guidelines, and clinical experience in Review.pdf

  118. BulletSevere community-acquired pneumonia review 2016.pdf

  119. BulletSevere community-acquired pneumonia.pdf

  120. BulletSevere Covid-19 Review 2020.pdf

  121. BulletSevere Hospital-Acquired Pneumonia Review.pdf

  122. BulletSevere infections in neutropenic patients Review 2015.pdf

  123. BulletSevere influenza Review 2019.pdf

  124. BulletSevere lactic acidosis reversed by thiamine within 24 hours letter.pdf

  125. BulletSevere pneumonia and a second antibiotic.pdf

  126. BulletSevere Pneumonia in Intensive Care.pdf

  127. BulletSevere pulmonary infections.pdf

  128. BulletSevere Sepsis and Septic Shock Review 2013.pdf

  129. BulletSevere sepsis and septic shock Review 2014 2.pdf

  130. BulletSevere Sepsis and Septic Shock Review 2014.pdf

  131. BulletSeverity assessment tools to guide ICU admission in community-acquired pneumonia.pdf

  132. BulletSeverity Scores and Community-acquired Pneumonia.pdf

  133. BulletShould Broad-Spectrum Antibiotics Be Routinely Administered to All Patients With Sepsis as Soon as Possible? Pro:Con 2019.pdf

  134. BulletShould the Surviving Sepsis Campaign Guidelines Be Retired? Pro:con.pdf

  135. BulletSignificance of Prior Digestive Colonization With Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae in Patients With Ventilator- Associated Pneumonia.pdf

  136. BulletSignificance of tracheal candida.pdf

  137. BulletSignificantly higher procalcitonin levels could differentiate Gram- negative sepsis from Gram-positive and fungal sepsis.pdf

  138. BulletSimultaneously Mounted Pro- and Anti-inflammatory Host Response Relates to the Development of Secondary Infections in Patients with Sepsis.pdf

  139. BulletSIRS in the Time of Sepsis-3.pdf

  140. BulletSkin antisepsis with chlorhexidine–alcohol versus povidone iodine–alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection.pdf

  141. BulletSOAP study.pdf

  142. BulletStandard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations.pdf

  143. BulletStaph aureus bacteremia review.pdf

  144. BulletStaphylococcal Toxic Shock Syndrome.pdf

  145. BulletStaphylococcus aureus bacteraemia.pdf

  146. BulletStaphylococcus aureus Community-acquired Pneumonia.pdf

  147. BulletStaphylococcus aureus Infections Review 2015.pdf

  148. BulletStaphylococcus aureus, Panton-Valentine leukocidin, and necrotising pneumonia.pdf

  149. BulletSteroid and Insulin treatment in ICU.pdf

  150. BulletSteroids in sepsis, etomidate and Pearl Harbor.pdf

  151. BulletSteroids in Septic Shock 1:08.pdf

  152. BulletSteroids in Septic shock Review.pdf

  153. BulletCorticosteroides in critical illness review .pdf

  154. BulletCorticus 08.pdf

  155. BulletSteroids and Meningitis.pdf

  156. BulletSteroids for sepsis Marik.pdf

  157. BulletSteroids in community-acquired pneumonia.pdf

  158. BulletSteroids in critical illness review .pdf

  159. BulletSteroids in Critical illness-Corticus 1:08.pdf

  160. BulletSteroids in sepsis, etomidate and Pearl Harbor.pdf

  161. BulletSteroids in Septic Shock 1:08.pdf

  162. BulletSteroids in Septic shock Review.pdf

  163. BulletStimulation of staph epidermis and biofilm formation by inotropes.pdf

  164. BulletStrategies to reduce curative antibiotic therapy in intensive care units.pdf

  165. BulletStreptococcal toxic shock syndrome in the intensive care unit Review 2018.pdf

  166. BulletStreptococcal Toxic-Shock Syndrome.pdf

  167. BulletStreptococcus pneumoniae and Pseudomonas aeruginosa pneumonia induce distinct host responses.pdf

  168. BulletSubglottic secretion drainage for the prevention of VAP review.pdf

  169. BulletSubphenotypes in critical care Review 2020.pdf

  170. BulletSuccessful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation.pdf

  171. BulletSuccessful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis.pdf

  172. BulletSurvival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death.pdf

  173. BulletSurviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU.pdf

  174. BulletSurviving the first hours in sepsis.pdf

  175. BulletSystematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis.pdf

  176. BulletSystemic Inflammatory Response Syndrome Criteria in Defining Severe Sepsis.pdf

  177. BulletTargeted versus universal decolonization to prevent ICU prevention.pdf

  178. BulletTargeting Hypoxia induced Inflammation.pdf

  179. BulletTen ineffective interventions to prevent ventilator-associated pneumonia.pdf

  180. BulletTen old antibiotics that will never disappear.pdf

  181. BulletTen things we learned about COVID-19.pdf

  182. BulletTen tips on how to win the war against resistance to antibiotics.pdf

  183. BulletThe Addition of Intravenous Metronidazole to Oral Vancomycin is Associated With Improved Mortality in Critically Ill Patients With Clostridium difficile Infection.pdf

  184. BulletThe Basics and the Advancements in Diagnosis of Bacterial Lower Respiratory Tract Infections 2019.pdf

  185. BulletThe Burden of Community-Acquired Pneumonia Requiring Admission to an ICU in the United States.pdf

  186. BulletThe case of the extracorporeal treatment of sepsis.pdf

  187. BulletThe challenge of recognising sepsis.pdf

  188. BulletThe challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients.pdf

  189. BulletThe Changing Paradigm of Sepsis Marik.pdf

  190. BulletThe clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock Review 2014.pdf

  191. BulletThe clinical picture of severe leptospirosis in critically ill patients.pdf

  192. BulletThe Cost-effectiveness of Corticosteroids for the treatment of Community-Acquired Pneumonia.pdf

  193. BulletThe critically ill patient with TB review 2018.pdf

  194. BulletThe critically ill patient with tuberculosis in intensive care Review 2018.pdf

  195. BulletThe digestive tract as the origin of systemic inflammation Review 2016.pdf

  196. BulletThe Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Us.pdf

  197. BulletThe duration of viral shedding of discharged patients with severe COVID-19.pdf

  198. BulletThe Effect of a Multidisciplinary Team Approach to Eradicate Central Line-Associated Bloodstream Infections.pdf

  199. BulletThe effects of antibiotic cycling and mixing on antibiotic resistance in intensive care units.pdf

  200. BulletThe Empirical Combination of Vancomycin and a Beta-Lactam for Staphylococcal Bacteremia.pdf

  201. BulletThe global challenge of Candida auris in the intensive care unit.pdf

  202. BulletThe Gut as the Motor of Multiple Organ Dysfunction in Critical Illness Review 2016.pdf

  203. BulletThe gut is the epicentre of antibiotic resistance.pdf

  204. BulletThe Human Intestinal Microbiome in Health and Disease.pdf

  205. BulletThe Impact of the Sepsis-3 Septic Shock Definition on Previously Defined Septic Shock Patients.pdf

  206. BulletThe Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock.pdf

  207. BulletThe importance of airway and lung microbiome in the critically ill Review 2020.pdf

  208. BulletThe influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09).pdf

  209. BulletThe Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patient Outcomes in the ICU Setting.pdf

  210. BulletThe Intensive Care Global Study on Severe Acute Respiratory Infection.pdf

  211. BulletThe Limitations of Sepsis-3.pdf

  212. BulletThe management of sepsis science & fiction 2020.pdf

  213. BulletThe microbiome and critical illness Review 2016.pdf

  214. BulletThe microbiome of the critically ill patient Review 2017.pdf

  215. BulletThe nephrotoxicity of aminoglycosides in severe sepsis or septic shock.pdf

  216. BulletThe neurocritical care of tuberculous meningitis Review 2019.pdf

  217. BulletThe new sepsis consensus definitions (Sepsis-3).pdf

  218. BulletThe Overton window and a less dogmatic approach to antibiotics.pdf

  219. BulletThe Prevalence and Significance of Methicillin-Resistant Staphylococcus aureus Colonization at Admission in the General ICU Setting.pdf

  220. BulletThe preventable proportion of nosocomial infections.pdf

  221. BulletThe radiographic resolution of Streptococcus pneumoniae.pdf

  222. BulletThe relationship between Candida species cultured from the respiratory tract and systemic inflammation in critically ill patients.pdf

  223. BulletThe research agenda in VAP:HAP.pdf

  224. BulletThe role of biomarkers in the diagnosis and management of community- acquired pneumonia.pdf

  225. BulletThe Search for Diagnostic Markers in Sepsis J Pugin.pdf

  226. BulletThe Role of Systemic Antibiotics in Acquiring Respiratory Tract Colonization With Gram-Negative Bacteria in Intensive Care Patients.pdf

  227. BulletThe Surviving Sepsis Campaign bundles and outcome.pdf

  228. BulletThe Systemic Inflammatory Response to Cardiac surgery review.pdf

  229. BulletThe Utility of Proadrenomedullin and Procalcitonin in Comparison to C-Reactive Protein as Predictors of Sepsis and Bloodstream Infections.pdf

  230. BulletThe value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis Review.pdf

  231. BulletThe Vibrio fischeri quorum-sensing systems ain and lux sequentially induce luminescence gene expression and are important for persistence in the squid host.pdf

  232. BulletThe zero-VAP sophistry and controversies surrounding prevention of ventilator-associated pneumonia.pdf

  233. BulletTherapeutic drug monitoring of the b-lactam antibiotics.pdf

  234. BulletTherapeutic drug monitoring-based dose optimisation of piperacillin and meropenem.pdf

  235. BulletTherapeutic management of peritonitis Review 2016.pdf

  236. BulletTherapeutic strategies in pneumonia going beyond antibiotics.pdf

  237. BulletTherapeutic targets in necrotizing soft tissue infections.pdf

  238. BulletTherapy for Burkholderia cepacia infections review.pdf

  239. BulletTherapy for sepsis edit.pdf

  240. BulletTherapy of VAP - Tarragona Strategy.pdf

  241. BulletThreat From Colistin-Resistant Superbug.pdf

  242. BulletTigecycline use in critically ill patients.pdf

  243. BulletTime from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock.pdf

  244. BulletTime to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia.pdf

  245. BulletTime to Treatment and Mortality during Mandated Emergency Care for Sepsis.pdf

  246. BulletTiming and causes of death in septic shock.pdf

  247. BulletTo Procalcitonin, or Not to Procalcitonin? 2019.pdf

  248. BulletTop Antimicrobial Stewardship Intervention Publications in 2017.pdf

  249. BulletToward Increased Understanding of the Steroid Controversy in Septic Shock 2019.pdf

  250. BulletToxic Shock Syndrome.pdf

  251. BulletTranscriptional Profiling is Superior to Procalcitonin to Discriminate Bacterial vs Viral Lower Respiratory Tract Infections in Hospitalized Adults.pdf

  252. BulletTransferable Vancomycin Resistance in a Community-Associated MRSA Lineage.pdf

  253. BulletTreating Critical Illness The Importance of First Doing No Harm.PDF

  254. BulletTreating patients with severe sepsis review.pdf

  255. BulletTreatment for infections with carbapenem- resistant Enterobacteriaceae Review 2014.pdf

  256. BulletTreatment for multidrug resistant and extensively drug resistant tuberculosis.pdf

  257. BulletTreatment Guidelines and Outcomes of Hospital Acquired and Ventilator-Associated Pneumonia.pdf

  258. BulletTreatment of central line-associated bloodstream infections 2018.pdf

  259. BulletTreatment of infections caused by multidrug-resistant Gram-negative bacteria Guidelines UK 2018.pdf

  260. BulletTreatment of Meningococcal Disease Review 2016.pdf

  261. BulletTreatment of Methicillin-Resistant Staphylococcus aureus Bacteremia Review 2017.pdf

  262. BulletTreatment of MRSA.pdf

  263. BulletTreatment Options for Carbapenem-resistant Gram- negative Bacterial Infections Review 2019.pdf

  264. BulletTreatment of severe MRSA infections.pdf

  265. BulletTrends in sepsis mortality over time in randomised sepsis trials 2019.pdf

  266. BulletTrial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery.pdf

  267. BulletTrials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.pdf

  268. BulletTuberculosis on the intensive care unit.pdf

  269. BulletTuberculosis septic shock, an elusive pathophysiology and hurdles in management Review 2019.pdf

  270. BulletTurbulent Gas Clouds and Respiratory Pathogen Emissions.pdf

  271. BulletTwo fatal cases of psittacosis caused by Chlamydophila psittaci.pdf

  272. BulletUltra short course antibiotics for patients with suspected ventilator-associated pneumonia but minimal and stable ventilator settings.pdf

  273. BulletUnderstanding chlorhexidine decolonization strategies.pdf

  274. BulletUnderstanding coma in bacterial meningitis.pdf

  275. BulletUnderstanding immunopathology of severe dengue Review 2020.pdf

  276. BulletUnderstanding lactatemia in human sepsis Gattinoni.pdf

  277. BulletUnderstanding necrotizing soft tissue infections in the intensive care unit 2020.pdf

  278. BulletUnderstanding resistance.pdf

  279. BulletUnderstanding the Inflammatory Cytokine Response in Pneumonia and Sepsis.pdf

  280. BulletUnderstanding the mechanisms and drivers of antimicrobial resistance Review 2016.pdf

  281. BulletUnderstanding toxic shock syndrome.pdf

  282. BulletUnraveling the nuances of innate immune regulation edit.pdf

  283. BulletUnravelling ceftazidime:avibactam resistance of KPC-28.pdf

  284. BulletUpdate in Lung Infections and Tuberculosis 2018.pdf

  285. BulletUpdate in Mycobacterium tuberculosis Lung Disease 2014.pdf

  286. BulletUpdate on Acinetobacter Review 2014.pdf

  287. BulletUpdate on ventilator-associated pneumonia Review 2015.pdf

  288. BulletUpdate on ventilator-associated pneumonia Review 2017.pdf

  289. BulletUpper airway samples to guide empiric antibiotics.pdf

  290. BulletUrgency in treating Septic Shock Edit..pdf

  291. BulletUse of antiviral agents in severe influenza.pdf

  292. BulletUse of Echinocandins in the Treatment of Candida Infections.pdf

  293. BulletUse of Transthoracic Echocardiography in the Management of Low-Risk Staphylococcus aureus bacteremia.pdf

  294. BulletUse of Vancomycin or First-Generation Cephalosporins for the Treatment of Hemodialysis- Dependent Patients with Methicillin-Susceptible Staphylococcus aureus Bacteremia.pdf

  295. BulletUsing Alveolar Neutrophilia to Diagnose Ventilator-associated Pneumonia.pdf

  296. BulletUsing procalcitonin to guide antimicrobial duration in sepsis.pdf

  297. BulletVancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia.pdf

  298. BulletVancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults.pdf

  299. BulletVancomycin Therapeutic Guidelines.pdf

  300. BulletVancomycin-Associated Nephrotoxicity in the Critically Ill.pdf

  301. BulletVap review 2012.pdf

  302. BulletVAP review 2016.pdf

  303. BulletVAP Review.pdf

  304. BulletVascular catheter colonization.pdf

  305. BulletVasculitis in ICU review.pdf

  306. BulletVentilator Associated Pneumonia and SDD.pdf

  307. BulletVentilator Associated Pneumonia Diagnosis Treatment and Prevention.pdf

  308. BulletVentilator associated Pneumonia head down position.pdf

  309. BulletVentilator associated pneumonia review 2012.pdf

  310. BulletVentilator associated pneumonia.pdf

  311. BulletVentilator-associated infection the role for inhaled antibiotics Review 2015.pdf

  312. BulletVentilator-associated Pneumonia and the Gastropulmonary Route of Infection.pdf

  313. BulletVentilator-associated Pneumonia Caused by ESKAPE Organisms.pdf

  314. BulletVentilator-Associated Pneumonia edit.pdf

  315. BulletVentilator-associated pneumonia in adults Review 2020.pdf

  316. BulletVentilator-associated pneumonia in the ICU review 2014.pdf

  317. BulletVentilator-associated pneumonia prevalence edit.pdf

  318. BulletVentilator-Associated Pneumonia Review 2014.pdf

  319. BulletVentilator-associated pneumonia review.pdf

  320. BulletVentilator-Associated Pneumonia The Clinical Pulmonary Infection Score (CPIS) as a Surrogate for Diagnostics and Outcome.pdf

  321. BulletVentilator-associated tracheobronchitis and pneumonia.pdf

  322. BulletVentilator-Associated Tracheobronchitis and Ventilator-Associated Pneumonia.pdf

  323. BulletVentilator-associated tracheobronchitis pre-emptive, appropriate antibiotic therapy recommended.pdf

  324. BulletViral infections in the intensive care unit Review.pdf

  325. BulletViral pneumonia Review 2018.pdf

  326. BulletVital Organ Blood Flow During Hyperdynamic Sepsis .pdf

  327. BulletVitamin S (Steroids) and Vitamin C for the Treatment of Severe Sepsis and Septic Shock Marik.pdf

  328. BulletWe need to optimize piperacillin- tazobactam dosing in critically ill patients—but how.pdf

  329. BulletWest Nile Virus BMC.pdf

  330. BulletWhat Have We Learned about the Use of Cytosorb Adsorption Columns?.pdf

  331. BulletWhat Healthcare Workers Should Know about Environmental Bacterial Contamination in the Intensive Care Unit.pdf

  332. BulletWhat is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients.pdf

  333. BulletWhat Is The Predominant Source of Intravascular Catheter Infections.pdf

  334. BulletWhat should we be doing about fungal infections in intensive care? edit.pdf

  335. BulletWhat's new in selective decontamination of the digestive tract 2016.pdf

  336. BulletWhat’s new in bacterial meningitis.pdf

  337. BulletWhat’s new in multidrug-resistant pathogens in the ICU Review 2016.pdf

  338. BulletWhat’s new in the extracorporeal treatment of sepsis?.pdf

  339. BulletWhy have clinical trials in sepsis failed Review?.pdf

  340. BulletWhy IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines.pdf

  341. BulletXuebijing in the treatment of patients with sepsis.pdf

  342. BulletWhat’s new in severe community-acquired pneumonia 2016.pdf

  343. BulletYear in review 2010 infection.pdf

  1. References


  1. Pod/vodCasts

  1. Presentations

• Other Interesting Sites

MEDIC’S CORNERMedics_Corner.htmlshapeimage_2_link_0